Robert Fuchs - ViewRay Chief Officer

VRAYDelisted Stock  USD 0.04  0  5.67%   

Insider

Robert Fuchs is Chief Officer of ViewRay
Age 56
Phone440 703 3210
Webhttps://www.viewray.com

ViewRay Management Efficiency

The company has return on total asset (ROA) of (0.2529) % which means that it has lost $0.2529 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0891) %, meaning that it created substantial loss on money invested by shareholders. ViewRay's management efficiency ratios could be used to measure how well ViewRay manages its routine affairs as well as how well it operates its assets and liabilities.
ViewRay currently holds 86.4 M in liabilities with Debt to Equity (D/E) ratio of 0.54, which is about average as compared to similar companies. ViewRay has a current ratio of 2.98, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ViewRay's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jared OasheimCVRx Inc
40
Michael FavetNeuropace
54
Nabil ShabshabInogen Inc
59
James BullockArtivion
64
Charles IIIAnika Therapeutics
N/A
Kevin MuirDelcath Systems
N/A
Thomas AckermanArtivion
66
Marna BorgstromArtivion
67
Heather BrennanEstablishment Labs Holdings
N/A
Ed JoyceAxogen Inc
N/A
John OrdwaySight Sciences
N/A
Jeffrey BettingerEstablishment Labs Holdings
N/A
David ColleranAnika Therapeutics
52
Shunichi KurodaBone Biologics Corp
N/A
Paul RodioEstablishment Labs Holdings
58
Matthew GetzArtivion
55
Rebecca KuhnNeuropace
63
Moji JamesAvanos Medical
N/A
Ryan SabiaTivic Health Systems
37
John MSDelcath Systems
63
Joshua WellsArtivion
N/A
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio. Viewray operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 267 people. ViewRay (VRAY) is traded on NASDAQ Exchange in USA and employs 295 people.

Management Performance

ViewRay Leadership Team

Elected by the shareholders, the ViewRay's board of directors comprises two types of representatives: ViewRay inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ViewRay. The board's role is to monitor ViewRay's management team and ensure that shareholders' interests are well served. ViewRay's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ViewRay's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert McCormack, Chief Officer
Robert Fuchs, Chief Officer
Zachary Stassen, Chief Officer
James Dempsey, Chief Scientific Officer, Director
Martin MD, Chief Officer
JD Ziegler, Chief Officer
Karen Hackstaff, VP Marketing
Scott Drake, CEO Pres
Matt Harrison, Director Relations
Drew Hill, VP Devel

ViewRay Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ViewRay a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Consideration for investing in ViewRay Stock

If you are still planning to invest in ViewRay check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ViewRay's history and understand the potential risks before investing.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated